Allena Pharmaceuticals Inc (ALNA) Holdings Boosted by Sphera Funds Management LTD.
Sphera Funds Management LTD. raised its holdings in Allena Pharmaceuticals Inc (NASDAQ:ALNA) by 10.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 295,199 shares of the company’s stock after purchasing an additional 27,850 shares during the period. Sphera Funds Management LTD.’s holdings in Allena Pharmaceuticals were worth $3,170,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Allena Pharmaceuticals in the 3rd quarter valued at approximately $116,000. Rhumbline Advisers acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter valued at approximately $133,000. Spark Investment Management LLC acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter valued at approximately $208,000. Acadian Asset Management LLC acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter valued at approximately $242,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Allena Pharmaceuticals in the 2nd quarter valued at approximately $282,000. 84.39% of the stock is currently owned by institutional investors.
Shares of NASDAQ ALNA opened at $9.26 on Friday. Allena Pharmaceuticals Inc has a twelve month low of $6.13 and a twelve month high of $17.56. The company has a quick ratio of 14.75, a current ratio of 14.75 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $189.76 million and a PE ratio of -1.93.
A number of equities analysts have issued reports on the company. Zacks Investment Research raised Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 15th. Wedbush reaffirmed a “buy” rating and issued a $38.00 target price on shares of Allena Pharmaceuticals in a research report on Tuesday, October 23rd. Finally, Jefferies Financial Group assumed coverage on Allena Pharmaceuticals in a research report on Thursday, November 8th. They issued a “buy” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Allena Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $29.14.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/allena-pharmaceuticals-inc-alna-holdings-boosted-by-sphera-funds-management-ltd/2670943.html.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Story: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding ALNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allena Pharmaceuticals Inc (NASDAQ:ALNA).
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.